Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MBX Biosciences, Inc. ( (MBX) ) has provided an announcement.
On June 16, 2025, MBX Biosciences announced the submission of an Investigational New Drug (IND) application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug intended for obesity treatment. The company plans to initiate a Phase 1 clinical trial in the third quarter of 2025, aiming to offer a once-monthly injectable with improved gastrointestinal tolerability and enhanced weight loss potential. This development marks a significant step in MBX’s strategy to leverage its PEP™ platform for creating advanced therapeutic options, potentially strengthening its position in the biopharmaceutical industry.
The most recent analyst rating on (MBX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on MBX Biosciences, Inc. stock, see the MBX Stock Forecast page.
Spark’s Take on MBX Stock
According to Spark, TipRanks’ AI Analyst, MBX is a Underperform.
MBX Biosciences faces significant challenges with its zero revenue and increasing losses, heavily impacting financial performance. Bearish technical indicators and valuation concerns compound the risks. While the strategic board appointment is a positive step, it does not offset the primary financial and operational difficulties.
To see Spark’s full report on MBX stock, click here.
More about MBX Biosciences, Inc.
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Carmel, Indiana, focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company utilizes its proprietary PEP™ platform to advance a pipeline of candidates targeting significant unmet medical needs and large market opportunities, including treatments for chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity.
Average Trading Volume: 289,748
Technical Sentiment Signal: Hold
Current Market Cap: $346.6M
See more data about MBX stock on TipRanks’ Stock Analysis page.